Cipla Ltd. is a pharmaceutical company based in India with a medium risk rating score of 25.6. Known for its focus on a wide range of pharmaceutical products, Cipla's product portfolio includes complex generics and drugs in various therapeutic segments such as respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and more. With a strong presence in India and globally, the company's growth strategy emphasizes new product launches. Cipla operates in two segments, Pharmaceuticals and new ventures. Upgrade your healthcare with Cipla Ltd., a leading ESG-friendly pharmaceutical company.